eRT Announces the Availability of the Suicidality Monitoring System(TM) For Clini...(ce Response (IVR) technology are: consta...),Health

Date:6/19/2008

ce Response (IVR) technology are: constant availability; reliable, consistent, and complete presentation of every question; electronic recording of respondents' answers; documentation of the assessment completion; and prompt feedback and reporting to the study sites. Patients are more likely to disclose sensitive subject matter, including suicidality, in computer interviews than they will to human interviewers. The SMS models the ideal human interviewer, comprehensively and consistently covering every relevant topic while efficiently branching around irrelevant questions. Sound science requires standardization of measurement; the SMS provides a standard of procedural reliability that surpasses the reliability of human investigators performing such assessments."

"Just as the use of digital ECGs in assessing cardiac safety has become an essential part of drug development, we believe that the use of SMS in assessing suicidality will also become an integral part of the drug development process," said Jeffrey S. Litwin, M.D., eRT's Chief Medical Officer.

EXPeRT(R) ePRO was launched by eRT in conjunction with Healthcare Technology Systems (HTS), a leading authority in the research, development and validation of computer administered clinical rating instruments. It leverages HTS' expertise and eRT's existing infrastructure and role as a leading provider of clinical solutions to the pharmaceutical, biotechnology, medical device and related industries. Electronic patient reported outcome (ePRO) assessments are standardized, with all questions asked and scored by direct automated methods from trial subjects at any location with telephone access. Additionally, ePRO assessments provide subject response checking during interviews, offer immediate data storage to prevent potential data loss, and improve the accuracy and timeliness of subject data entry and increased clinical study efficiencies.

About eResearchTechnology, Inc.

Philadelphia-based eResear
'/>"/>

SOURCE eResearchTechnology, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Pilot Therapeutics Announces Relaunch as Gene Smart(TM) Health
2. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
3. Oridion Announces Major Medical Research and Congress Presentations
4. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
5. Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
6. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
7. Disc Motion Technologies Announces First Human Implants of True TSMS(TM) Device
8. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
9. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
10. Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
11. XTENT Announces European Regulatory Update